Clinical trials: Allogeneic Hematopoietic Stem Cell Transplantation
Acute Myeloblastic Leukemia, Lymphoblastic Leukemia
Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant
The purpose of this study is to compare Reduced Intensity Conditioning protocols containing either Thymoglobuline or Alemtuzumab in patients undergoing allogeneic transplant from voluntary unrelated donors.
- Conditions
- Acute Myeloblastic Leukemia, Lymphoblastic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia
- Trial name
- GLOBAL (NCT00354120)
- Testing
- Alentuzumab, Globulina antilinfocitaria
- Where
- 22 sites in Italy
- Volunteers
- 121 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Patients With Type 1 Diabetes
Allogeneic Islet Transplantation for the Treatment of Type 1 Diabetes
It is a multicentre, sequential, phase II clinical trial, aiming at evaluating the allogeneic islet transplantation for the treatment of type 1 diabetes.
- Trial name
- GRIIF (NCT01974674)
- Testing
- Allogeneic transplantation of intrahepatic islet
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma) whose disease has returned or not…
- Conditions
- CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type, Anaplastic Large Cell Lymphoma, ALK-Positive, Peripheral T-cell Lymphoma
- Trial name
- CABAL2 (NCT06176690)
- Testing
- C7R.CD30.CAR-EBVST cells
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Baylor College of Medicine
Hodgkins Lymphoma
Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma
The investigators intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from EBV positive HLA matched sibling or unrelated adult donor combined with post AlloSCT allogeneic donor derived LMP…
- Trial name
- NCT01636388
- Testing
- allogeneic donor derived LMP specific cytotoxic T-lymphocyte
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- New York Medical College
Graft vs Host Disease
Fecal Microbiota Transplantation for Steroid-Refractory Acute GI GVHD
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for various hematologic diseases. However, one of the major challenges of allo-HSCT is the occurrence of graft-versus-host disease (GvHD)…
- Trial name
- NCT07364617
- Testing
- Fecal microbiota transplantation (FMT)
- Where
- Taiwan
- Volunteers
- 35 people
- Sponsor
- Chang Gung Memorial Hospital
Graft-vs-Host Disease (GVHD)
Treatment of Refractory (Acute or Chronic) Graft-Versus-Host Disease by the Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell
Clinical trial based on the use of a new therapeutic strategy (MSC infusion) for the treatment of patients who have developed a GVHD refractory to the usual therapeutic measures after undergoing an allogenic hematopoietic stem…
- Trial name
- NCT00447460
- Testing
- Mesenchymal stem cell (MSC)
- Where
- 4 sites in Spain
- Volunteers
- 15 people
- Sponsor
- University of Salamanca
Allogenic Hematopoietic Cell Transplant, CAR-T Therapy
COVID-19 Vaccine in Patients After Allogeneic HCT, CAR-T Therapy and With Primary Immune Deficiency
The corona pandemic is a continuing global challenge due to Corona Virus 2019 (COVID-19). The purpose of the study is to confirm the accepted hypothesis from the recommendations of The European Society for Blood and Marrow…
- Conditions
- Allogenic Hematopoietic Cell Transplant, CAR-T Therapy, Primary Immunodeficiency
- Trial name
- NCT04724642
- Where
- Israel
- Volunteers
- 110 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Acute Lymphoblastic Leukaemia, Acute Leukemia of Ambiguous Lineage
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial
The goal of this clinical trial is to test the ability to restore gut microbiota to healthier levels in patients with blood cancers scheduled to have stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukaemia, Acute Leukemia of Ambiguous Lineage, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- MAST (NCT06355583)
- Testing
- EBX-102
- Where
- 8 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Imperial College London
Classical Hodgkin Lymphoma
Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
The aim of the trial is to improve disease control after an allogeneic stem cell transplantation (alloSCT) for relapsed or refractory classical Hodgkin lymphoma (rrHL, cHL) with consolidation therapy by Brentuximab Vedotin (BV)…
- Trial name
- NCT03652441
- Testing
- Brentuximab Vedotin
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- University of Cologne
Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
This research study is studying a drug that may help decrease the chances of relapse after Allogeneic Stem Cell transplantation for Acute Myeloid Leukemia. The name of the study drug involved in this study is: Ruxolitinib
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Allogeneic Stem Cell Transplantation
- Trial name
- NCT03286530
- Testing
- Ruxolitinib
- Where
- 6 sites in United States
- Volunteers
- 64 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma, Plasma Cell Neoplasm
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
RATIONALE: Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells.
- Trial name
- NCT00028600
- Testing
- filgrastim, CD34+ cells, cyclophosphamide
- Where
- 15 sites in United States
- Volunteers
- 60 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Allografts, Oral cGVHD
The Oral cGVHD as a Predictive Factor of Graft Versus Leukaemia Effect in Patients Who Received an Allograft
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the standard treatment for many malignant blood disorders. Its effectiveness is based on the graft-versus-leukemia (GVL) effect, which is intrinsically linked to…
- Trial name
- NCT07271498
- Testing
- Evaluation of oral cGVHD
- Where
- France
- Volunteers
- 93 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Acute Myeloid Leukaemia, Myelodysplastic Syndrome
GITMO AML/MDS-Relapse Registry Study
The proposal arises from the increasingly pressing need to have a program of therapy for the prevention of relapse after allogeneic transplantation in patients with acute myeloid leukemia or myelodysplasia, especially if they…
- Trial name
- NCT06790680
- Where
- Italy
- Volunteers
- 859 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
This phase I/II trial studies how well autologous stem cell transplant followed by donor stem cell transplant works in treating patients with lymphoma that has returned or does not respond to treatment.
- Conditions
- Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma
- Trial name
- NCT00005803
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation, Carmustine
- Where
- 5 sites in United States, Germany
- Volunteers
- 76 people
- Sponsor
- Fred Hutchinson Cancer Center
Osteoarthritis, Knee
Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium Therapy for Osteoartrithis
This study aims to compare the efficacy of Umbilical Cord Mesenchymal Stem Cell and secretome between arthroscopy and without arthroscopy intervention in OA patients.
- Trial name
- OA (NCT04314661)
- Testing
- Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome, Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome, Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome
- Where
- Indonesia
- Volunteers
- 31 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Musculoskeletal Injury
A Study of Human Allogeneic Bone-marrow Derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Musculoskeletal Injuries and/or Degeneration
The goal of this ongoing open-label, single-arm, phase I/IIa study in patients is designed to assess the safety of human allogeneic BM-derived MSCs product StromaForte for musculoskeletal injury or/and degeneration.
- Trial name
- NCT06074783
- Testing
- Human Allogeneic Bone-Marrow (BM) -Derived Mesenchymal Stromal Cells (MSCs) Product (StromaForte)
- Where
- The Bahamas
- Volunteers
- 30 people
- Sponsor
- Cellcolabs Clinical LTD.
Highly Sensitized Prospective Kidney Transplant Recipients
Carfilzomib and Belatacept for Desensitization
Some kidney transplant candidates have a very low chance of getting a kidney transplant because their immune systems are "highly sensitized" to most kidney donors.
- Trial name
- ADAPT (NCT05017545)
- Testing
- carfilzomib, belatacept, Bone marrow aspiration
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia
This is a a phase 1, open label study to assess the safety and efficacy of ThisCART19 (Allogeneic CAR-T targeting CD19) Bridging Hematopoietic Stem Cell Transplantation in patients with refractory or relapsed B cell acute…
- Trial name
- NCT05576181
- Testing
- ThisCART19A, Fludarabine Oral Tablet, Cyclophosphamide
- Volunteers
- 19 people
- Sponsor
- Fundamenta Therapeutics, Ltd.
B-Cell Lymphomas
Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients
The aim of this study is rate of acute graft-versus-host disease II-IV measured at day +365according to conventional criteria (Przepiorka et al.
- Trial name
- NCT01613300
- Testing
- Ofatumumab
- Where
- 10 sites in Spain
- Volunteers
- 33 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
BK Virus Infection
Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes
This research study is evaluating the reactivation of BK virus in patients who have undergone allogeneic hematopoietic-cell transplantation.
- Trial name
- NCT03532971
- Testing
- Symptom index questionnaire, BK polyomavirus PCR, quality of life questionnaires
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Dana-Farber Cancer Institute